Engineering antibody therapeutics

Current Opinion in Structural Biology

Volumn 38, Issue , 2016, Pages 163-173

  Chiu, Mark L ^a   Gilliland, Gary L ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; ANTIBODY;

ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIGEN BINDING; B LYMPHOCYTE; BINDING AFFINITY; DRUG MANUFACTURE; EUKARYOTE; HUMAN; HYBRIDOMA; IMMUNIZATION; IMMUNOGLOBULIN VARIABLE REGION; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RIBOSOME; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; PROCEDURES; PROTEIN ENGINEERING; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES; HUMANS; PROTEIN ENGINEERING; TISSUE DISTRIBUTION;

EID: 84981517828     PISSN: 0959440X     EISSN: 1879033X     Source Type: Journal    
DOI: 10.1016/j.sbi.2016.07.012     Document Type: Review

References (99)

1. 1 Reichert, J.M., Antibodies to watch in 2016. MAbs 8 (2016), 197–204.
2. 2 Kohler, G., Milstein, C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975), 495–497.
3. 3 Omidfar, K., Daneshpour, M., Advances in phage display technology for drug discovery. Expert Opin Drug Discov 10 (2015), 651–669.
4. 4 McCafferty, J., Schofield, D., Identification of optimal protein binders through the use of large genetically encoded display libraries. Curr Opin Chem Biol 26 (2015), 16–24.
5. 5• Bruggemann, M., Osborn, M.J., Ma, B., Hayre, J., Avis, S., Lundstrom, B., Buelow, R., Human antibody production in transgenic animals. Arch Immunol Ther Exp (Warsz) 63 (2015), 101–108 Progress on generating human antibodies from transgenic mammals.
6. 6•• Spiess, C., Zhai, Q., Carter, P.J., Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 67 (2015), 95–106 Review of bispecific and multispecific molecules using antibody fusions and alternative scaffolds.
7. 7• Bournazos, S., Ravetch, J.V., Fcgamma receptor pathways during active and passive immunization. Immunol Rev 268 (2015), 88–103 Excellent review of the different biological activities arising from Fc receptor engagement.
8. 8•• Beers, S.A., Glennie, M.J., White, A.L., Influence of immunoglobulin isotype on therapeutic antibody function. Blood 127 (2016), 1097–1101 Critical review of isotype selection for therapeutic antibodies targeting different mechanisms of action.
9. 9 Stapleton, N.M., Einarsdottir, H.K., Stemerding, A.M., Vidarsson, G., The multiple facets of FcRn in immunity. Immunol Rev 268 (2015), 253–268.
10. 10• Gilliland, G.L., Luo, J., Vafa, O., Almagro, J.C., Leveraging SBDD in protein therapeutic development: antibody engineering. Methods Mol Biol 841 (2012), 321–349 Review of structure based therapeutic antibody engineering to guide affinity, Fc effector function, and biophysical properties.
11. 11 Chothia, C., Lesk, A.M., Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196 (1987), 901–917.
12. 12 Adolf-Bryfogle, J., Xu, Q., North, B., Lehmann, A., Dunbrack, R.L. Jr., PyIgClassify: a database of antibody CDR structural classifications. Nucleic Acids Res 43 (2015), D432–D438.
13. 13 North, B., Lehmann, A., Dunbrack, R.L. Jr., A new clustering of antibody CDR loop conformations. J Mol Biol 406 (2011), 228–256.
14. 14 Morrison, S.L., Johnson, M.J., Herzenberg, L.A., Oi, V.T., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 81 (1984), 6851–6855.
15. 15 Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S., Winter, G., Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 (1986), 522–525.
16. 16 Laffleur, B., Pascal, V., Sirac, C., Cogne, M., Production of human or humanized antibodies in mice. Methods Mol Biol 901 (2012), 149–159.
17. 17 Smith, G.P., Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228 (1985), 1315–1317.
18. 18 Hoogenboom, H.R., Selecting and screening recombinant antibody libraries. Nat Biotechnol 23 (2005), 1105–1116.
19. 19 Osbourn, J., Groves, M., Vaughan, T., From rodent reagents to human therapeutics using antibody guided selection. Methods 36 (2005), 61–68.
20. 20 Marks, J.D., Hoogenboom, H.R., Bonnert, T.P., McCafferty, J., Griffiths, A.D., Winter, G., By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222 (1991), 581–597.
21. 21 Rothe, C., Urlinger, S., Lohning, C., Prassler, J., Stark, Y., Jager, U., Hubner, B., Bardroff, M., Pradel, I., Boss, M., et al. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 376 (2008), 1182–1200.
22. 22• Adams, J.J., Sidhu, S.S., Synthetic antibody technologies. Curr Opin Struct Biol 24 (2014), 1–9 Review of design strategies to obtain diverse high affinity antibodies.
23. 23 Gai, S.A., Wittrup, K.D., Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol 17 (2007), 467–473.
24. 24 Harvey, B.R., Georgiou, G., Hayhurst, A., Jeong, K.J., Iverson, B.L., Rogers, G.K., Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc Natl Acad Sci U S A 101 (2004), 9193–9198.
25. 25 Smith, E.S., Zauderer, M., Antibody library display on a mammalian virus vector: combining the advantages of both phage and yeast display into one technology. Curr Drug Discov Technol 11 (2014), 48–55.
26. 26 Smith, K., Garman, L., Wrammert, J., Zheng, N.Y., Capra, J.D., Ahmed, R., Wilson, P.C., Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 4 (2009), 372–384.
27. 27 Kwakkenbos, M.J., Bakker, A.Q., van Helden, P.M., Wagner, K., Yasuda, E., Spits, H., Beaumont, T., Genetic manipulation of B cells for the isolation of rare therapeutic antibodies from the human repertoire. Methods 65 (2014), 38–43.
28. 28 Jin, A., Ozawa, T., Tajiri, K., Obata, T., Kondo, S., Kinoshita, K., Kadowaki, S., Takahashi, K., Sugiyama, T., Kishi, H., et al. A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. Nat Med 15 (2009), 1088–1092.
29. 29 Ogunniyi, A.O., Story, C.M., Papa, E., Guillen, E., Love, J.C., Screening individual hybridomas by microengraving to discover monoclonal antibodies. Nat Protoc 4 (2009), 767–782.
30. 30 Tiller, T., Single B cell antibody technologies. N Biotechnol 28 (2011), 453–457.
31. 31• Duvall, M.R., Fiorini, R.N., Different approaches for obtaining antibodies from human B cells. Curr Drug Discov Technol 11 (2014), 41–47 Review on methods to obtain antibodies directly from human B cells.
32. 32 Wrammert, J., Smith, K., Miller, J., Langley, W.A., Kokko, K., Larsen, C., Zheng, N.Y., Mays, I., Garman, L., Helms, C., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453 (2008), 667–671.
33. 33 Scheid, J.F., Mouquet, H., Feldhahn, N., Seaman, M.S., Velinzon, K., Pietzsch, J., Ott, R.G., Anthony, R.M., Zebroski, H., Hurley, A., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458 (2009), 636–640.
34. 34 Mietzner, B., Tsuiji, M., Scheid, J., Velinzon, K., Tiller, T., Abraham, K., Gonzalez, J.B., Pascual, V., Stichweh, D., Wardemann, H., et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci U S A 105 (2008), 9727–9732.
35. 35 Buttel, I.C., Chamberlain, P., Chowers, Y., Ehmann, F., Greinacher, A., Jefferis, R., Kramer, D., Kropshofer, H., Lloyd, P., Lubiniecki, A., et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39 (2011), 100–109.
36. 36 Wu, S.-J., Gilliland, G.L., Feng, F., Solubility and early assessment of stability. Das, T.K., (eds.) Biophysical Methods for Biotherapeutics: Discovery and Development Applications, 2014, John Wiley & Sons, 65–91.
37. 37 Yang, W.P., Green, K., Pinz-Sweeney, S., Briones, A.T., Burton, D.R., Barbas, C.F. 3rd, CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 254 (1995), 392–403.
38. 38 Raghunathan, G., Smart, J., Williams, J., Almagro, J.C., Antigen-binding site anatomy and somatic mutations in antibodies that recognize different types of antigens. J Mol Recognit 25 (2012), 103–113.
39. 39 Kiyoshi, M., Caaveiro, J.M., Miura, E., Nagatoishi, S., Nakakido, M., Soga, S., Shirai, H., Kawabata, S., Tsumoto, K., Affinity improvement of a therapeutic antibody by structure-based computational design: generation of electrostatic interactions in the transition state stabilizes the antibody–antigen complex. PLOS ONE, 9, 2014, e87099.
40. 40 Takeda, K., Kojima, Y., Uno, T., Hayakawa, Y., Teng, M.W., Yoshizawa, H., Yagita, H., Gejyo, F., Okumura, K., Smyth, M.J., Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J Immunol 184 (2010), 5493–5501.
41. 41 Gu, J., Ghayur, T., Rationale and development of multispecific antibody drugs. Expert Rev Clin Pharmacol 3 (2010), 491–508.
42. 42•• Kontermann, R.E., Brinkmann, U., Bispecific antibodies. Drug Discov Today 20 (2015), 838–847 Description of novel therapeutic mechanism of actions for bispecific antibodies.
43. 43 Mazor, Y., Oganesyan, V., Yang, C., Hansen, A., Wang, J., Liu, H., Sachsenmeier, K., Carlson, M., Gadre, D.V., Borrok, M.J., et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs 7 (2015), 377–389.
44. 44 Liu, Z., Leng, E.C., Gunasekaran, K., Pentony, M., Shen, M., Howard, M., Stoops, J., Manchulenko, K., Razinkov, V., Liu, H., et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem 290 (2015), 7535–7562.
45. 45 Miller, B.R., Demarest, S.J., Lugovskoy, A., Huang, F., Wu, X., Snyder, W.B., Croner, L.J., Wang, N., Amatucci, A., Michaelson, J.S., et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 23 (2010), 549–557.
46. 46 Wu, X., Sereno, A.J., Huang, F., Lewis, S.M., Lieu, R.L., Weldon, C., Torres, C., Fine, C., Batt, M.A., Fitchett, J.R., et al. Fab-based bispecific antibody formats with robust biophysical properties and biological activity. MAbs 7 (2015), 470–482.
47. 47 Grote, M., Haas, A.K., Klein, C., Schaefer, W., Brinkmann, U., Bispecific antibody derivatives based on full-length IgG formats. Methods Mol Biol 901 (2012), 247–263.
48. 48 Benson, J.M., Sachs, C.W., Treacy, G., Zhou, H., Pendley, C.E., Brodmerkel, C.M., Shankar, G., Mascelli, M.A., Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol 29 (2011), 615–624.
49. 49 Bostrom, J., Yu, S.F., Kan, D., Appleton, B.A., Lee, C.V., Billeci, K., Man, W., Peale, F., Ross, S., Wiesmann, C., et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323 (2009), 1610–1614.
50. 50 Jakob, C.G., Edalji, R., Judge, R.A., DiGiammarino, E., Li, Y., Gu, J., Ghayur, T., Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig) molecule. MAbs 5 (2013), 358–363.
51. 51 Fischer, N., Elson, G., Magistrelli, G., Dheilly, E., Fouque, N., Laurendon, A., Gueneau, F., Ravn, U., Depoisier, J.F., Moine, V., et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun, 6, 2015, 6113.
52. 52 Carter, P., Bispecific human IgG by design. J Immunol Methods 248 (2001), 7–15.
53. 53 Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S.B., Born, T., Retter, M., Manchulenko, K., et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 285 (2010), 19637–19646.
54. 54 Schaefer, W., Regula, J.T., Bahner, M., Schanzer, J., Croasdale, R., Durr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 108 (2011), 11187–11192.
55. 55 Muda, M., Gross, A.W., Dawson, J.P., He, C., Kurosawa, E., Schweickhardt, R., Dugas, M., Soloviev, M., Bernhardt, A., Fischer, D., et al. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. Protein Eng Des Sel 24 (2011), 447–454.
56. 56 Tustian, A.D., Endicott, C., Adams, B., Mattila, J., Bak, H., Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. MAbs, 2016, 10.1080/19420862.2016.1160192:0.
57. 57 Muller-Spath, T., Ulmer, N., Aumann, L., Strohlein, G., Bavand, M., Hendriks, L., De Kruif, J., Throsby, M., Bakker, A., Purifying common light-chain bispecific antibodies: a twin-column, countercurrent chromatography platform process. Bioprocess Intl. 11 (2013), 36–45.
58. 58 Lewis, S.M., Wu, X., Pustilnik, A., Sereno, A., Huang, F., Rick, H.L., Guntas, G., Leaver-Fay, A., Smith, E.M., Ho, C., et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 32 (2014), 191–198.
59. 59• Labrijn, A.F., Meesters, J.I., de Goeij, B.E., van den Bremer, E.T., Neijssen, J., van Kampen, M.D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M.J., et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 110 (2013), 5145–5150 Generation of an intact and stable human bispecific antibody with minimal number of mutations.
60. 60• Strop, P., Ho, W.H., Boustany, L.M., Abdiche, Y.N., Lindquist, K.C., Farias, S.E., Rickert, M., Appah, C.T., Pascua, E., Radcliffe, T., et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 420 (2012), 204–219 Generation of human bispecific IgG1 and IgG2 antibodies.
61. 61 Gramer, M.J., van den Bremer, E.T., van Kampen, M.D., Kundu, A., Kopfmann, P., Etter, E., Stinehelfer, D., Long, J., Lannom, T., Noordergraaf, E.H., et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches. MAbs 5 (2013), 962–973.
62. 62 Schoch, A., Kettenberger, H., Mundigl, O., Winter, G., Engert, J., Heinrich, J., Emrich, T., Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A 112 (2015), 5997–6002.
63. 63 Li, B., Tesar, D., Boswell, C.A., Cahaya, H.S., Wong, A., Zhang, J., Meng, Y.G., Eigenbrot, C., Pantua, H., Diao, J., et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs 6 (2014), 1255–1264.
64. 64 Jefferis, R., Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 7 (2007), 1401–1413.
65. 65•• Jefferis, R., Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 526 (2012), 159–166 Excellent review of the role of glycosylation on the activity of antibodies that can be put into different isotypes.
66. 66 Monnet, C., Jorieux, S., Urbain, R., Fournier, N., Bouayadi, K., De Romeuf, C., Behrens, C.K., Fontayne, A., Mondon, P., Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions. Front Immunol, 6, 2015, 39.
67. 67 Diebolder, C.A., Beurskens, F.J., de Jong, R.N., Koning, R.I., Strumane, K., Lindorfer, M.A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A.J., et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343 (2014), 1260–1263.
68. 68•• Teeling, J.L., Mackus, W.J., Wiegman, L.J., van den Brakel, J.H., Beers, S.A., French, R.R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J.W., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177 (2006), 362–371 Excellent comparison of the role of anti-CD20 antibody epitopes drive the biological activity.
69. 69 Martin, W.L., West, A.P. Jr., Gan, L., Bjorkman, P.J., Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 7 (2001), 867–877.
70. 70 Hinton, P.R., Xiong, J.M., Johlfs, M.G., Tang, M.T., Keller, S., Tsurushita, N., An engineered human IgG1 antibody with longer serum half-life. J Immunol 176 (2006), 346–356.
71. 71 Dall'Acqua, W.F., Kiener, P.A., Wu, H., Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281 (2006), 23514–23524.
72. 72 Datta-Mannan, A., Witcher, D.R., Tang, Y., Watkins, J., Wroblewski, V.J., Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 282 (2007), 1709–1717.
73. 73 Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., Yamaguchi, T., Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 184 (2010), 1968–1976.
74. 74 Jefferis, R., Lefranc, M.P., Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 1 (2009), 332–338.
75. 75 Ternant, D., Arnoult, C., Pugniere, M., Dhommee, C., Drocourt, D., Perouzel, E., Passot, C., Baroukh, N., Mulleman, D., Tiraby, G., et al. IgG1 allotypes influence the pharmacokinetics of therapeutic monoclonal antibodies through FcRn binding. J Immunol 196 (2016), 607–613.
76. 76 Wang, W., Singh, S., Zeng, D.L., King, K., Nema, S., Antibody structure, instability, and formulation. J Pharm Sci 96 (2007), 1–26.
77. 77• Yang, X., Xu, W., Dukleska, S., Benchaar, S., Mengisen, S., Antochshuk, V., Cheung, J., Mann, L., Babadjanova, Z., Rowand, J., et al. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies. MAbs 5 (2013), 787–794 Review of quality by design using stress conditions and solubility to screen antibody candidates.
78. 78 Manning, M.C., Chou, D.K., Murphy, B.M., Payne, R.W., Katayama, D.S., Stability of protein pharmaceuticals: an update. Pharm Res 27 (2010), 544–575.
79. 79 Zhang, B., Yang, Y., Yuk, I., Pai, R., McKay, P., Eigenbrot, C., Dennis, M., Katta, V., Francissen, K.C., Unveiling a glycation hot spot in a recombinant humanized monoclonal antibody. Anal Chem 80 (2008), 2379–2390.
80. 80 Miller, A.K., Hambly, D.M., Kerwin, B.A., Treuheit, M.J., Gadgil, H.S., Characterization of site-specific glycation during process development of a human therapeutic monoclonal antibody. J Pharm Sci 100 (2011), 2543–2550.
81. 81 Dillon, T.M., Ricci, M.S., Vezina, C., Flynn, G.C., Liu, Y.D., Rehder, D.S., Plant, M., Henkle, B., Li, Y., Deechongkit, S., et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 283 (2008), 16206–16215.
82. 82 Vlasak, J., Ionescu, R., Fragmentation of monoclonal antibodies. MAbs 3 (2011), 253–263.
83. 83 Wu, H., Kroe-Barrett, R., Singh, S., Robinson, A.S., Roberts, C.J., Competing aggregation pathways for monoclonal antibodies. FEBS Lett 588 (2014), 936–941.
84. 84 Liu, H., Ponniah, G., Zhang, H.M., Nowak, C., Neill, A., Gonzalez-Lopez, N., Patel, R., Cheng, G., Kita, A.Z., Andrien, B., In vitro and in vivo modifications of recombinant and human IgG antibodies. MAbs 6 (2014), 1145–1154.
85. 85 Roberts, C.J., Therapeutic protein aggregation: mechanisms, design, and control. Trends Biotechnol 32 (2014), 372–380.
86. 86 Jefferis, R., Glycosylation of antibody therapeutics: optimisation for purpose. Methods Mol Biol 483 (2009), 223–238.
87. 87• Alsenaidy, M.A., Jain, N.K., Kim, J.H., Middaugh, C.R., Volkin, D.B., Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles. Front Pharmacol, 5, 2014, 39 The use of different biophysical and analytical tools to characterize protein physical stability for the selection of candidate biotherapeutic molecules.
88. 88•• Jarasch, A., Koll, H., Regula, J.T., Bader, M., Papadimitriou, A., Kettenberger, H., Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci 104 (2015), 1885–1898 The use of small-scale, rapid methods that can identify candidates with better biochemical and biophysical properties.
89. 89• Agrawal, N.J., Kumar, S., Wang, X., Helk, B., Singh, S.K., Trout, B.L., Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions. J Pharm Sci 100 (2011), 5081–5095 Sequence-structure-based approach to identify aggregation prone sequences in antibodies.
90. 90 Rouet, R., Lowe, D., Christ, D., Stability engineering of the human antibody repertoire. FEBS Lett 588 (2014), 269–277.
91. 91 Swift, J., Saing, S., Rouet, R., Dudgeon, K., Schofield, P., Sewell, W., Christ, D., Identification of aggregation inhibitors of the human antibody light chain repertoire by phage display. Protein Eng Des Sel 27 (2014), 405–409.
92. 92• Shire, S.J., Formulation and manufacturability of biologics. Curr Opin Biotechnol 20 (2009), 708–714 Review of changes in the manufacturing process and formulation development to maximize the successful manufacture of therapeutic antibodies.
93. 93• Lowe, D., Dudgeon, K., Rouet, R., Schofield, P., Jermutus, L., Christ, D., Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 84 (2011), 41–61 Overview of the methods to characterize antibody aggregation and the role of engineering and formulation to mitigate such risks.
94. 94 Higel, F., Seidl, A., Sorgel, F., Friess, W., N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. Eur J Pharm Biopharm 100 (2016), 94–100.
95. 95 Jefferis, R., Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8 (2009), 226–234.
96. 96 Mozziconacci, O., Okbazghi, S., More, A.S., Volkin, D.B., Tolbert, T., Schoneich, C., Comparative evaluation of the chemical stability of 4 well-defined immunoglobulin G1-Fc glycoforms. J Pharm Sci 105 (2016), 575–587.
97. 97 More, A.S., Toprani, V.M., Okbazghi, S.Z., Kim, J.H., Joshi, S.B., Middaugh, C.R., Tolbert, T.J., Volkin, D.B., Correlating the impact of well-defined oligosaccharide structures on physical stability profiles of IgG1-Fc glycoforms. J Pharm Sci 105 (2016), 588–601.
98. 98 Wacker, C., Berger, C.N., Girard, P., Meier, R., Glycosylation profiles of therapeutic antibody pharmaceuticals. Eur J Pharm Biopharm 79 (2011), 503–507.
99. 99 Reusch, D., Tejada, M.L., Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 25 (2015), 1325–1334.